Dr Beadle is the Chief Executive Officer of Psioxus Therapeutics Ltd., a private company developing immuno-oncology therapeutics and headquartered in Oxford, UK with offices near Philadelphia, USA. PsiOxus is focused upon developing oncolytic viruses for the treatment of solid tumors utilising the proprietary Tumor Specific Immuno Gene Therapy (T-SiGn) platform. The company has two clinical stage collaborations with BMS and an extensive pre-clinical follow-on pipeline. John was previously Co-founder and Chief Medical Officer of PowderMed Ltd., a private Oxford, UK biotech company, which he helped to build and lead before a successful trade sale in 2007 to Pfizer. He then became Entrepreneur in Residence at Imperial College London and has held the role of CEO in a number of start-up and early stage biotech companies. He was CEO of both Myotec Therapeutics and Hybrid Biosytems, before merging the two companies in 2011 to form PsiOxus Therapeutics.
In his early career, John held Research and Development roles of ascending seniority within The Wellcome Foundation, GlaxoWellcome and GlaxoSmithkline, where he was most recently the Vice President of Global Medical Operations. He was then Vice President of Product Development at the vaccines company PowderJect. John graduated as a Medical Doctor from the University of Witwatersrand and received his Masters of Business Administration from the London Business School.